YUALLS DONT NEED CANUCKLEHEAD STUFF---AT ANY COST
AstraZeneca, which will supply up to 20 million doses of its viral vector vaccine candidate AZD1222.
Sanofi and GlaxoSmithKline, which will supply up to 72 million of doses of their protein subunit vaccine candidate.
Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate Ad26.COV2.S.
Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate NVX-CoV2373.
Pfizer, which will supply a minimum of 20 million doses of its mRNA vaccine candidate, BNT162. The government is negotiating with the company to expand the agreement to include options for obtaining additional doses.
Moderna, which will supply up to 56 million doseS
AstraZeneca, which will supply up to 20 million doses of its viral vector vaccine candidate AZD1222.
Sanofi and GlaxoSmithKline, which will supply up to 72 million of doses of their protein subunit vaccine candidate.
Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate Ad26.COV2.S.
Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate NVX-CoV2373.
Pfizer, which will supply a minimum of 20 million doses of its mRNA vaccine candidate, BNT162. The government is negotiating with the company to expand the agreement to include options for obtaining additional doses.
Moderna, which will supply up to 56 million doseS
Recent MIR News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:07:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:06:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:08:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2026 08:48:26 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:30:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 08:06:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:16:37 PM
- Mirion Announces First Quarter 2026 Financial Results • Business Wire • 04/28/2026 08:15:00 PM
- Mirion Announces Earnings Release and Conference Call Date for First Quarter 2026 • Business Wire • 04/16/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 12:15:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:17:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:16:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:16:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:14:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 09:11:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:07:26 PM
- Mirion to Present at Citi’s 2026 Global Industrial Tech and Mobility Conference • Business Wire • 02/13/2026 01:30:00 PM
- Mirion Announces Executive Appointments to Accelerate Strategic Growth and Market Focus • Business Wire • 02/11/2026 02:19:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 09:17:14 PM
- Mirion Announces Fourth Quarter and Full Year 2025 Financial Results; Provides Full Year 2026 Guidance • Business Wire • 02/10/2026 09:15:00 PM
- Mirion Announces Earnings Release and Conference Call Date for Fourth Quarter and Full Year 2025 • Business Wire • 01/22/2026 01:30:00 PM
